Boston Scientific (BSX)

The company’s portfolio spans several large clinical markets. In cardiovascular care, Boston Scientific supplies technologies for interventional cardiology, peripheral vascular disease, electrophysiology, and cardiac rhythm management, including devices used to open blocked arteries, manage abnormal heart rhythms, and reduce stroke risk in selected patients. Its endoscopy business supports diagnosis and treatment in the gastrointestinal and pulmonary systems, while its urology and pelvic health products address kidney stones, enlarged prostate, incontinence, and related conditions. Boston Scientific also sells neuromodulation systems used to treat chronic pain and neurological disorders.

Boston Scientific competes in regulated markets where clinical evidence, physician training, product reliability, and reimbursement are central to adoption. The company sells directly and through distributors to healthcare professionals and institutions around the world, with international markets contributing a substantial share of revenue. Its growth depends on procedure volumes, new product launches, acquisitions, regulatory approvals, and the ability to demonstrate improved outcomes or efficiency compared with existing treatments. Boston Scientific is distinctive for the breadth of its minimally invasive device portfolio and its exposure to multiple specialist areas rather than reliance on a single therapeutic category.